Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
RF Acquisition Corp II ( (RFAI) ) just unveiled an announcement.
On October 2, 2025, RF Acquisition Corp II announced a business combination agreement with Nanyang Biologics Pte. Ltd., aimed at making NYB a publicly listed company. The transaction, valued at approximately $1.5 billion, will see the combined company listed on Nasdaq under the ticker symbol ‘NYB’. The agreement involves merging RFAC II with PubCo and amalgamating Amalgamation Sub with Nanyang, with Nanyang becoming a wholly-owned subsidiary of PubCo. The transaction is expected to close in the first or second quarter of 2026, pending shareholder approval and customary conditions. This strategic move is set to enhance NYB’s market positioning by accelerating drug discovery and expanding its reach in the pharmaceutical industry.
More about RF Acquisition Corp II
Nanyang Biologics Pte. Ltd. (NYB) is an AI-driven drug discovery and biotechnology company. It offers a comprehensive drug discovery platform that integrates traditional medicine with advanced technologies. NYB’s flagship Vecura™ AI platform, powered by its proprietary Drug-Target Interaction Graph Neural Network (DTIGN), is designed to identify promising drug candidates efficiently. The company focuses on oncology, cardiovascular, and mental health therapeutics, with a strong portfolio of patents and collaborations, including a joint laboratory with Nanyang Technological University Singapore.
Average Trading Volume: 7,943
Technical Sentiment Signal: Buy
Current Market Cap: $160M
See more data about RFAI stock on TipRanks’ Stock Analysis page.